The AHA Aug. 28 urged the Drug Enforcement Administration to reconsider its proposed 2019 aggregate production quotas for certain controlled substances, which the agency said would reduce manufacturing quotas for six frequently misused opioids by an average 10 percent. “Hospitals and other providers are currently facing critical shortages of a number of injectable opioid medications for which that the DEA recommends quota reductions, including morphine, hydromorphone, and fentanyl,” AHA said in a letter to DEA. “These decreases would exacerbate these already dire shortages.” AHA said its request is “specific to these injectable medopications and does not extend to other dosage forms or opioid products.” Comments are due Sept. 19.

Related News Articles

Headline
The National Institutes of Health today selected several universities to partner with communities in Kentucky, Massachusetts, New York and Ohio to study the…
Headline
The Food and Drug Administration yesterday announced changes to the prescribing information included in outpatient opioid pain medication labels.
Headline
The Agency for Healthcare Research and Quality is accepting comments through April 25 on a draft report on treatment for acute pain.
Headline
The Food and Drug Administration plans to revise its 2016 draft compounding guidance for hospital and health system pharmacies.
Headline
The Department of Health and Human Services this week awarded $487 million in fiscal year 2019 grants to help states and territories increase access to…
Headline
The three medications approved by the Food and Drug Administration to treat opioid use disorder — methadone, buprenorphine and extended-release naltrexone —…